TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic... TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic conditions. Its lead product, BRIUMVI (ublituximab‑xiiy), is an anti‑CD20 monoclonal antibody indicated for relapsing forms of multiple sclerosis, addressing a key segment of the neurology market where efficacy, infusion profile, and safety are central considerations. The company’s revenue base has increasingly centered on BRIUMVI’s U.S. uptake, reflecting its strategic transition from development to commercial execution and providing a recurring product revenue foundation. TG Therapeutics operates within the broader pharmaceuticals sector and is tracked on international venues including the Italian market under a global equity listing framework, with third‑party services providing pricing, market data, and coverage for investors and analysts. Its positioning highlights the role of targeted B‑cell therapies in autoimmune disease management, and its activities contribute to innovation pipelines and competitive dynamics among neurologic and immunology therapeutics developers.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by TG Therapeutics

We reviewed TG Therapeutics's website and available disclosure materials for the 2023 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review TG Therapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for TG Therapeutics.

Legal Center Contact Us